Bill
S 2257
Bar carriers, TPAs, PBMs, and certain state plans may not require pre-approval for any covered tests, procedures, or drugs prescribed by licensed providers.
Status
- Introduced (state level bill). Referred to Senate Commerce Committee. Placed on Senate calendar 07/10/2025.
- Effective date in text: “shall take effect immediately” and applies to health or prescription drug plans issued or purchased on or after that date.
Purpose and intent
- To eliminate prior authorization / precertification requirements for medical tests, procedures, and prescription drugs that are otherwise covered under a health or prescription drug benefits plan when those items are prescribed by a licensed health care provider. The sponsor’s stated intent is to reduce delays and administrative burden that impede patient access to medically‑necessary care.
Key provisions
- Carriers: A carrier may not condition payment for any medical test, procedure, or prescription drug on any form of pre‑approval or precertification if the item is covered under the plan and prescribed by a licensed provider.
- Third‑party administrators (TPAs): TPAs may not require pre‑approval or precertification as a condition of payment for covered tests, procedures, or prescription drugs ordered by a licensed provider.
- Pharmacy benefits managers (PBMs): PBMs may not condition payment for a prescription drug on any pre‑approval or precertification by the PBM, carrier, or purchaser when the drug is covered and prescribed by a licensed provider.
- State employee plans: Contracts for health or prescription drug benefits purchased by the State Health Benefits Program and the School Employees’ Health Benefits Program may not include pre‑approval or precertification requirements for covered items prescribed by a licensed provider.
- Supersession language: The prohibition is framed “notwithstanding any other law, rule or regulation,” indicating it would override conflicting state requirements.
Who is affected
- Directly: health insurers/carriers, TPAs, PBMs, state and school employee health programs.
- Indirectly: patients (especially those covered by affected plans), prescribing clinicians, employers who purchase coverage, and state regulators who oversee insurance contracts and plan compliance.
Potential impacts and implementation considerations
- Access and timeliness: Expected to speed patient access to tests, procedures, and medications by removing prior authorization delays.
- Administrative burden: Reduces paperwork and provider time spent on utilization management appeals and authorization processes.
- Cost and utilization: Insurers and PBMs may see increased utilization or spending on items formerly subject to utilization management; this could affect premiums or plan design unless offset by other cost controls.
- Quality and safety: Prior authorization programs are often used to manage high‑cost therapies, ensure appropriate use, or limit off‑label prescribing; removing them could require alternative safeguards (not specified in the bill).
- Enforcement and oversight: The bill text does not specify penalties or the enforcement mechanism; existing insurance oversight bodies would likely be responsible for compliance review and enforcement under general insurance law.
- Scope limits: The statute applies only to items “otherwise covered” under the plan and that are “prescribed by a licensed health care provider.” It does not expressly address exceptions (e.g., controlled substances, step therapy policies) or carve outs; those would be determined by subsequent regulation or litigation.
Related measures
- The record mentions companion or related bills in other jurisdictions (listed as HR 3944, HR 4249, HR 5371, A 5571), indicating similar proposals may be advancing elsewhere.
Bottom line
S 2257 would bar carriers, TPAs, PBMs, and certain state health programs from requiring prior authorization for covered tests, procedures, and drugs ordered by licensed providers, with the goal of speeding access and reducing administrative barriers. The bill leaves open financing, utilization, quality‑assurance, and enforcement details that will determine its practical effects on costs, care patterns, and regulatory oversight.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
